SCHEMBL5145131

SCHEMBL5145131

O=C1NC(=S)NC1=Cc1ccc(-c2ccc(Cl)c(C(=O)O)c2)o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 9/20 0.76
GSK3B P49841 9/20 0.76
TTR P02766 1/20 0.64
KMT2A Q03164 6/20 0.63
KDM4E B2RXH2 5/20 0.63
POLB P06746 5/20 0.63
TDP1 Q9NUW8 5/20 0.63
L3MBTL1 Q9Y468 5/20 0.63
MEN1 O00255 5/20 0.63
MAPT P10636 4/20 0.63
APEX1 P27695 4/20 0.63
RECQL P46063 3/20 0.63
CTDSP1 Q9GZU7 3/20 0.63
PTPN1 P18031 1/20 0.63
ALDH1A1 P00352 4/20 0.62
AURKA O14965 1/20 0.61
AURKB Q96GD4 1/20 0.61
SIRT2 Q8IXJ6 1/20 0.60
PRF1 P14222 1/20 0.56
ALPL P05186 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145124 1.00 GSK3A (0.76) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL5147289 0.91 GSK3A (0.76) GSK3AGSK3BKMT2AKDM4EPOLB
SCHEMBL5147286 0.91 GSK3A (0.76) GSK3AGSK3BKMT2AKDM4EPOLB
SCHEMBL5145154 0.88 GSK3A (0.78) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL5145152 0.88 GSK3A (0.78) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL15506584 0.86 GSK3A (1.00) GSK3AGSK3BKMT2AL3MBTL1MEN1
SCHEMBL3360967 0.82 TTR (0.82) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL30657767 0.82 TTR (0.82) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL3360964 0.82 TTR (0.82) GSK3AGSK3BTTRKMT2AKDM4E
SCHEMBL12989661 0.82 TTR (0.82) GSK3AGSK3BTTRKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
US-6943188-B2 Hydroxyalkyl compounds ASTRAZENECA AB (SE) 2005-09-13 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed
US-20030149047-A1 Novel compounds ASTRAZENCA AB (SE) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149047-A1 Novel compounds RPS4Y1, RPS4X, RPS6 GSK3A 2650/4885GSK3B 2220/4885TTR 3405/4885
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 GSK3A 2087/4885GSK3B 2118/4885TTR 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.